JP2012512814A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012512814A5 JP2012512814A5 JP2011541029A JP2011541029A JP2012512814A5 JP 2012512814 A5 JP2012512814 A5 JP 2012512814A5 JP 2011541029 A JP2011541029 A JP 2011541029A JP 2011541029 A JP2011541029 A JP 2011541029A JP 2012512814 A5 JP2012512814 A5 JP 2012512814A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- pharmaceutical composition
- composition according
- antagonist
- csf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002193 Pain Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 230000003042 antagnostic Effects 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 claims 1
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 230000003349 osteoarthritic Effects 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
Claims (9)
- 対象における疼痛の治療のためのＧＭ−ＣＳＦアンタゴニストを含む医薬組成物。
- 前記対象が、ヒトであることを特徴とする請求項１に記載の医薬組成物。
- 前記アンタゴニストが、ＧＭ−ＣＳＦに特異的な抗体であることを特徴とする請求項１に記載の医薬組成物。
- 前記アンタゴニストが、ＧＭ−ＣＳＦ受容体に特異的な抗体であることを特徴とする請求項１に記載の医薬組成物。
- 前記疼痛が、外科的手術後の疼痛であることを特徴とする請求項１に記載の医薬組成物。
- 前記疼痛が、骨肉腫の疼痛であることを特徴とする請求項１に記載の医薬組成物。
- 前記疼痛が、関節リウマチ痛であることを特徴とする請求項１に記載の医薬組成物。
- 前記疼痛が、変形性関節症痛であることを特徴とする請求項１に記載の医薬組成物。
- 前記疼痛が、炎症性疼痛であることを特徴とする請求項１に記載の医薬組成物。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13968708P | 2008-12-22 | 2008-12-22 | |
| US61/139,687 | 2008-12-22 | ||
| US16449109P | 2009-03-30 | 2009-03-30 | |
| US61/164,491 | 2009-03-30 | ||
| PCT/AU2009/001671 WO2010071923A1 (en) | 2008-12-22 | 2009-12-21 | Pain treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014138170A Division JP6147704B2 (ja) | 2008-12-22 | 2014-07-04 | 疼痛治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012512814A JP2012512814A (ja) | 2012-06-07 |
| JP2012512814A5 true JP2012512814A5 (ja) | 2013-02-14 |
| JP5674677B2 JP5674677B2 (ja) | 2015-02-25 |
Family
ID=42286785
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011541029A Active JP5674677B2 (ja) | 2008-12-22 | 2009-12-21 | 疼痛治療 |
| JP2014138170A Active JP6147704B2 (ja) | 2008-12-22 | 2014-07-04 | 疼痛治療 |
| JP2017074868A Pending JP2017149740A (ja) | 2008-12-22 | 2017-04-05 | 疼痛治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014138170A Active JP6147704B2 (ja) | 2008-12-22 | 2014-07-04 | 疼痛治療 |
| JP2017074868A Pending JP2017149740A (ja) | 2008-12-22 | 2017-04-05 | 疼痛治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8475796B2 (ja) |
| EP (2) | EP3381471B1 (ja) |
| JP (3) | JP5674677B2 (ja) |
| KR (1) | KR101761324B1 (ja) |
| CN (2) | CN102256621B (ja) |
| AU (2) | AU2009329811B2 (ja) |
| BR (1) | BRPI0918103A2 (ja) |
| CA (1) | CA2747206C (ja) |
| ES (2) | ES2685895T3 (ja) |
| HK (2) | HK1255046A1 (ja) |
| RU (2) | RU2712166C2 (ja) |
| WO (1) | WO2010071923A1 (ja) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3381471B1 (en) | 2008-12-22 | 2024-03-20 | The University of Melbourne | Pain treatment |
| CN106397591A (zh) | 2008-12-22 | 2017-02-15 | 墨尔本大学 | 骨关节炎治疗 |
| KR20210021153A (ko) * | 2012-09-20 | 2021-02-24 | 모르포시스 아게 | 류마티스 관절염에 대한 치료 |
| JP2015533806A (ja) * | 2012-09-20 | 2015-11-26 | モルフォシス・アー・ゲー | 関節リウマチの治療 |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res (Munich) Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| US9833410B2 (en) | 2012-10-31 | 2017-12-05 | Takeda Gmbh | Lyophilized formulation comprising GM-CSF neutralizing compound |
| WO2014138862A1 (en) * | 2013-03-14 | 2014-09-18 | John Schrader | Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof |
| US10745475B2 (en) | 2013-08-30 | 2020-08-18 | Takeda Gmbh | Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics |
| CN107840885B (zh) * | 2016-09-19 | 2020-11-10 | 天境生物科技(上海)有限公司 | Gm-csf抗体及其用途 |
| UA126565C2 (uk) * | 2016-09-19 | 2022-11-02 | Ай-Маб Байофарма (Ханчжоу) Ко., Лтд. | Антитіло до гм-ксф |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU630496B2 (en) * | 1989-07-14 | 1992-10-29 | Schering Corporation | Antagonists of gm-csf derived from the carboxyl terminus |
| DE69031914T2 (de) | 1989-08-11 | 1998-07-30 | Amrad Corp. Ltd., Kew, Victoria | Rezeptor für granulozyten-macrophagen-koloniestimulierungsfaktor und seine derivate |
| WO1994009149A1 (en) | 1990-08-10 | 1994-04-28 | Amrad Corporation Limited | Monoclonal antibody |
| AU5611394A (en) * | 1992-11-19 | 1994-06-08 | Dana-Farber Cancer Institute | Antibodies for gm-csf receptor and uses thereof |
| DK0859841T3 (da) | 1995-08-18 | 2002-09-09 | Morphosys Ag | Protein/(poly)peptidbiblioteker |
| AUPP525198A0 (en) | 1998-08-13 | 1998-09-03 | Medvet Science Pty. Ltd. | Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof |
| US7108852B2 (en) | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| US7455836B2 (en) | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
| SE0102067D0 (sv) * | 2001-06-11 | 2001-06-11 | A & Science Invest Ab | Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation |
| US20060067938A1 (en) | 2001-10-26 | 2006-03-30 | Sherif Daouti | Methods for the treatment of osteoarthritis and compositions thereof |
| WO2003068920A2 (en) | 2002-02-13 | 2003-08-21 | Ludwig Institute For Cancer Research | Humanized gm-csf antibodies |
| AU2002950957A0 (en) * | 2002-08-23 | 2002-09-12 | The Walter And Eliza Hall Institute Of Medical Research | A method of treatment and prophylaxis |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| US20040241755A1 (en) | 2003-06-02 | 2004-12-02 | Pfizer Inc. | Human cell assay to determine effect of sample compounds on Col2 enhancer expression |
| CA2561530C (en) | 2004-03-31 | 2014-04-22 | Kazuwa Nakao | Therapeutic or prophylactic agent for arthritis |
| DE602004021773D1 (de) | 2004-05-05 | 2009-08-13 | Micromet Ag | Herstellung eines einkettigen fv Antikörperfragments |
| ME02191B (me) | 2005-04-18 | 2016-02-20 | Amgen Res Munich Gmbh | Protutijela koja neutraliziraju ljudski čimbenik stimuliranja kolonija makrofaga |
| DK3620171T3 (da) * | 2005-05-18 | 2022-06-07 | Morphosys Ag | Anti-GM-CSF-antistoffer og anvendelser af disse |
| JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| TW200736276A (en) | 2005-12-01 | 2007-10-01 | Domantis Ltd | Competitive domain antibody formats that bind interleukin 1 receptor type 1 |
| PL1981909T3 (pl) | 2006-02-08 | 2017-08-31 | Morphotek, Inc. | Antygenowe peptydy GM-CSF oraz przeciwciała wobec GM-CSF |
| CN103641916A (zh) | 2006-03-27 | 2014-03-19 | 医学免疫有限公司 | Gm-csf受体结合元件 |
| US7741273B2 (en) * | 2006-04-13 | 2010-06-22 | Warsaw Orthopedic, Inc. | Drug depot implant designs |
| MX2009005398A (es) | 2006-11-21 | 2009-08-20 | Kalobios Pharmaceuticals Inc | Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf. |
| WO2008080134A2 (en) | 2006-12-22 | 2008-07-03 | Rigel Pharmaceuticals, Inc. | 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors |
| CA2687791A1 (en) | 2007-05-23 | 2008-11-27 | Crc For Asthma And Airways Ltd | Neutralizing antibodies |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| WO2009062238A1 (en) | 2007-11-12 | 2009-05-22 | Crc For Asthma And Airways Ltd | Epitope for neutralizing antibodies |
| CL2008003361A1 (es) | 2007-11-13 | 2010-02-05 | Boehringer Ingelheim Int | Anticuerpos monoclonales que se unen al hgm-csf y las composicones medias que los comprenden. |
| JP5688363B2 (ja) | 2008-04-28 | 2015-03-25 | カロバイオス ファーマシューティカルズ インコーポレイティッド | 顆粒球−マクロファージコロニー刺激因子に対する抗体 |
| CN106397591A (zh) | 2008-12-22 | 2017-02-15 | 墨尔本大学 | 骨关节炎治疗 |
| EP3381471B1 (en) * | 2008-12-22 | 2024-03-20 | The University of Melbourne | Pain treatment |
| US8609101B2 (en) | 2009-04-23 | 2013-12-17 | Theraclone Sciences, Inc. | Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies |
-
2009
- 2009-12-21 EP EP18170226.7A patent/EP3381471B1/en active Active
- 2009-12-21 WO PCT/AU2009/001671 patent/WO2010071923A1/en active Application Filing
- 2009-12-21 ES ES09833923.7T patent/ES2685895T3/es active Active
- 2009-12-21 AU AU2009329811A patent/AU2009329811B2/en active Active
- 2009-12-21 CA CA2747206A patent/CA2747206C/en active Active
- 2009-12-21 EP EP09833923.7A patent/EP2387418B1/en active Active
- 2009-12-21 US US13/140,839 patent/US8475796B2/en active Active
- 2009-12-21 BR BRPI0918103A patent/BRPI0918103A2/pt not_active Application Discontinuation
- 2009-12-21 RU RU2016102346A patent/RU2712166C2/ru active
- 2009-12-21 JP JP2011541029A patent/JP5674677B2/ja active Active
- 2009-12-21 CN CN200980151639.7A patent/CN102256621B/zh active Active
- 2009-12-21 RU RU2011127333A patent/RU2630969C2/ru active
- 2009-12-21 CN CN201711112956.0A patent/CN108014335A/zh active Pending
- 2009-12-21 KR KR1020117017019A patent/KR101761324B1/ko active IP Right Grant
- 2009-12-21 ES ES18170226T patent/ES2978209T3/es active Active
-
2013
- 2013-05-28 US US13/903,009 patent/US9352034B2/en active Active
-
2014
- 2014-07-04 JP JP2014138170A patent/JP6147704B2/ja active Active
-
2016
- 2016-01-18 AU AU2016200267A patent/AU2016200267B2/en active Active
- 2016-04-29 US US15/142,746 patent/US9834599B2/en active Active
-
2017
- 2017-04-05 JP JP2017074868A patent/JP2017149740A/ja active Pending
-
2018
- 2018-11-07 HK HK18114170.3A patent/HK1255046A1/zh unknown
- 2018-11-09 HK HK18114356.9A patent/HK1255227A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012512814A5 (ja) | ||
| CY2017039I1 (el) | Αντισωματα υψηλης συγγενειας στον υποδοχεα της ανθρωπινης ιl-6 | |
| BRPI1012116A2 (pt) | composição farmacêutica para o tratamento de doenças cardíacas | |
| SMT201700102B (it) | Anticorpi umani di alta affinitá al recettore attivato dalle proteasi-2 umano | |
| LTC2152290I2 (lt) | Anti-il-5 antikūnų skyrimo būdai | |
| JP2011006431A5 (ja) | ||
| CR10379A (es) | Composiones farmaceuticas de antagonistas del anticuerpo anti-cd40. | |
| CL2007001993A1 (es) | Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat | |
| IL225519A0 (en) | Effective preparations and methods for the treatment and diagnosis of inflammatory bowel disease | |
| IL215579A (en) | Use of 1-benzyl-3-hydroxymethylindazole history to prepare medicinal products for the treatment of diseases based on the expression of 1-mcp, cx3cr1 and 40p | |
| JP2013014622A5 (ja) | ||
| JP2012512815A5 (ja) | ||
| HUE038313T2 (hu) | Protofibril-kötõ antitestek és alkalmazásuk Parkinson-kór, Lewy-testes demencia és más alfa-szinukleinopátiák terápiás és diagnosztikai eljárásaiban | |
| CL2006002831A1 (es) | Compuestos derivados de sulfonamida: proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad mediada por el receptor de glucocorticoides. | |
| FR2962437B1 (fr) | Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique | |
| BRPI1013426A2 (pt) | organismos para produção de 1,3-butanodiol | |
| IL205948A (en) | Antidotes eta 14–3–3 and their uses in the diagnosis and treatment of arthritis | |
| FR2941696B1 (fr) | Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique | |
| BR112012018374A2 (pt) | derivados de ácido carboxílico de pirrolidina ou tiazolidina, composição farmacêutica e métodos para uso no tratamento de distúrbios metabólicos como agonistas de receptor 43 acoplado à proteína g (gpr43). | |
| RU2016102346A (ru) | Лечение боли | |
| CL2013001591A1 (es) | Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades. | |
| JP2012136529A5 (ja) | ||
| BRPI0812964A2 (pt) | Forma de dosagem farmacêutica oral sólida | |
| CL2014000079A1 (es) | El compuesto n-(6-((2r,3s)-3,4-dihidroxibutan-2iloxi)-2-(4-fluorobenciltio) pirimidin-4-ilo)-3-metilacetidina-1-sulfonamida, receptor de qumiocina; forma cristalina; proceso de preparación; compuesto intermediario; composicion farmaceutica; y su uso en asma, rinitis alergica, epoc, sindrome de colon irritable, enfermedad intestinal inflamatoria, entre otras | |
| DK2448940T3 (da) | Derivater af 6,7,8,9 tetrahydro-pyrimido{1,2-a}pyrimidin-4-on, fremstilling og farmaceutisk anvendelse heraf |